Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

Welcome to the European Journal of Immunology, a premier peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Established in 1971 and published by Wiley, this esteemed journal has been consistently ranked in the top quartile (Q1) across its categories, highlighting its significant impact within the scientific community. With an impressive Scopus ranking, the journal occupies the 64th position in Immunology and Allergy and the 74th in the broader sector of Immunology and Microbiology, demonstrating its vital role in driving innovation and knowledge in immunological studies. The European Journal of Immunology publishes high-quality original research, comprehensive reviews, and insightful commentary, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to understanding the complexities of the immune system. Although not an open-access journal, it offers various subscription options to ensure that institutions and individuals can access pivotal research that shapes the future of immunology.

IMUNOLOGY AND CELL BIOLOGY, published by Wiley, serves as a prominent platform for disseminating cutting-edge research in the fields of immunology and cell biology. With an ISSN of 0818-9641 and an E-ISSN of 1440-1711, this journal has established itself since its inception in 1987, demonstrating a commitment to advancing knowledge in its disciplines through high-quality articles. Renowned for its rigorous peer-review process, it holds a Q2 quartile ranking in both immunology and cell biology categories as of 2023, showing its competitive stature in these fields. IMUNOLOGY AND CELL BIOLOGY is indexed among the elite journals worldwide, with impressive Scopus rankings, including a rank of #75/233 in Immunology and Allergy. The journal’s comprehensive scope ensures that it caters to an audience of researchers, professionals, and students who are dedicated to exploring the intricate mechanisms of immune responses and cellular interactions. Although it does not operate under an open access model, its subscription-based content remains invaluable for those seeking to broaden their understanding of immunology and cell biology. By providing a forum for significant scientific dialogue, IMUNOLOGY AND CELL BIOLOGY continues to shape the future of research in these vital areas.

Cellular & Molecular Immunology is a prestigious peer-reviewed journal published by the CHIN SOCIETY IMMUNOLOGY. As a leading journal in the fields of immunology and infectious diseases, it proudly holds a Q1 designation across multiple categories, including Immunology, Allergy, and Medicine (Miscellaneous), reflecting its commitment to excellence and impactful research. With an ISSN of 1672-7681 and an E-ISSN of 2042-0226, the journal has been essential reading since its inception in 2004, continuously gathering insights from cutting-edge studies. It ranks impressively within Scopus, with positions in the 7th, 8th, and 9th percentile in relevant categories, establishing it as a cornerstone for researchers, clinicians, and students alike. The journal offers an extensive range of original research articles, reviews, and clinical studies, ensuring that readers stay at the forefront of immunological discovery. Whether you are interested in basic immunology, infectious diseases, or evolving therapies, Cellular & Molecular Immunology serves as an invaluable resource for advancing your knowledge and engagement in this dynamic field.

Journal of Immunotoxicology, published by Taylor & Francis Ltd, is at the forefront of research in the intersecting fields of immunology and toxicology. With an annual impact factor that reflects its growing influence, this Open Access journal has been essential for disseminating valuable knowledge since its inception in 2004. The journal welcomes novel research articles, reviews, and commentary that explore the effects of xenobiotics on the immune system, contributing to a deeper understanding of immunotoxicological mechanisms and implications for human health. As a recognized platform, it has achieved commendable rankings in Scopus, positioning it within Q3 in Immunology and Q2 in Toxicology categories as of 2023. This ensures that the journal remains a critical resource for researchers, professionals, and students seeking to advance their knowledge and contribute to the evolving landscape of immunotoxicology. With an Open Access model since 2017, it maximizes accessibility and reaches a global audience, supporting the collaborative efforts needed to address contemporary challenges in health and safety.

Mucosal Immunology, published by Elsevier Science Inc, is a leading journal dedicated to advancing the field of immunology with a particular focus on mucosal immunity. Since its inception in 2008, the journal has established itself as a premier source of cutting-edge research, evidenced by its impressive Q1 ranking in both Immunology and Allergy for 2023, and its notable positions within the top ranks of Scopus (Rank #21/233 in Immunology and Allergy and Rank #24/236 in Immunology and Microbiology). The journal serves as a vital resource for researchers, professionals, and students aiming to explore the complexities of mucosal immune responses and their implications in health and disease. While it operates under a subscription model, Mucosal Immunology is committed to disseminating quality research globally and enhancing collaborative efforts within the scientific community. Explore the latest findings and connect with influential scholarship in this rapidly evolving field.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.